About Alkermes
Alkermes is a company based in Dublin (Ireland) founded in 1987.. The company has 1,800 employees as of December 31, 2024. Alkermes has completed 2 acquisitions, including Avadel Pharmaceuticals and Rodin Therapeutics. Alkermes offers products and services including Olanzapine and samidorphan, ALKS 2680, ALKS 4510, and ALKS 7290. Alkermes operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Dublin, Ireland
- Employees 1800 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Alkermes Plc
-
Annual Revenue
$1.56 B-6.36as on Dec 31, 2024
-
Net Profit
$367.07 M3.18as on Dec 31, 2024
-
EBITDA
$449.17 M-8.15as on Dec 31, 2024
-
Latest Funding Round
$2.31 M (USD), Grant
Sep 30, 2010
- Investors
-
Employee Count
1800
as on Dec 31, 2024
-
Investments & Acquisitions
Avadel Pharmaceuticals
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Alkermes
Alkermes is a publicly listed company on the NASDAQ with ticker symbol ALKS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Alkermes
Alkermes offers a comprehensive portfolio of products and services, including Olanzapine and samidorphan, ALKS 2680, ALKS 4510, and ALKS 7290. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for schizophrenia and bipolar disorder in adults.
Therapy for narcolepsy and idiopathic hypersomnia conditions.
Investigational treatment for central nervous system disorders.
Potential therapy for neurological and psychiatric issues.
Unlock access to complete
Unlock access to complete
Leadership Team
128 people
Software Development Team
119 people
Sales and Marketing
48 people
Senior Team
41 people
Legal and Compliance
23 people
Product Management Team
22 people
Data Analysis and Operations Team
22 people
Operations Team
20 people
Unlock access to complete
Funding Insights of Alkermes
- Total Funding Total Funding
- Total Rounds 5
- Last Round Grant — $2.3M
-
First Round
First Round
(19 Mar 1997)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2010 | Amount | Grant - Alkermes | Valuation |
investors |
|
| Feb, 2005 | Amount | Debt – Venture - Alkermes | Valuation |
investors |
|
| Aug, 2003 | Amount | Post-IPO - Alkermes | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Alkermes
Alkermes has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Alkermes
Alkermes has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Avadel Pharmaceuticals and Rodin Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Epigenetic modulators are developed for CNS disorder treatments.
|
2013 | ||||
|
Proprietary drug delivery technologies and narcolepsy treatments are developed.
|
1990 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Alkermes
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Alkermes Comparisons
Competitors of Alkermes
Alkermes operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| domain | founded_year | HQ Location |
Gene and protein therapies are developed for treating various diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Alkermes
Frequently Asked Questions about Alkermes
When was Alkermes founded?
Alkermes was founded in 1987 and raised its 1st funding round 10 years after it was founded.
Where is Alkermes located?
Alkermes is headquartered in Dublin, Ireland.
How many employees does Alkermes have?
As of Dec 31, 2024, the latest employee count at Alkermes is 1,800.
What is the annual revenue of Alkermes?
Annual revenue of Alkermes is $1.56B as on Dec 31, 2024.
What does Alkermes do?
Alkermes was founded in 1987 and is based in Dublin, Ireland. Small molecule therapeutics and drug delivery technologies are developed for central nervous system (CNS) diseases. A diversified commercial product portfolio is maintained, alongside a clinical pipeline of candidates for chronic conditions including schizophrenia, depression, addiction, and multiple sclerosis. Operations focus on advancing treatments in the biopharmaceutical sector.
Who are the top competitors of Alkermes?
Alkermes's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
What products or services does Alkermes offer?
Alkermes offers Olanzapine and samidorphan, ALKS 2680, ALKS 4510, and ALKS 7290.
Is Alkermes publicly traded?
Yes, Alkermes is publicly traded on NASDAQ under the ticker symbol ALKS.
How many acquisitions has Alkermes made?
Alkermes has made 2 acquisitions, including Avadel Pharmaceuticals, and Rodin Therapeutics.
Who are Alkermes's investors?
Alkermes has 1 investor. Key investors include HHS.
What is Alkermes's ticker symbol?
The ticker symbol of Alkermes is ALKS on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.